Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study.

Buchsbaum MS, Hollander E, Haznedar MM, Tang C, Spiegel-Cohen J, Wei TC, Solimando A, Buchsbaum BR, Robins D, Bienstock C, Cartwright C, Mosovich S.

Int J Neuropsychopharmacol. 2001 Jun;4(2):119-25.

PMID:
11466160
2.

Limbic circuitry in patients with autism spectrum disorders studied with positron emission tomography and magnetic resonance imaging.

Haznedar MM, Buchsbaum MS, Wei TC, Hof PR, Cartwright C, Bienstock CA, Hollander E.

Am J Psychiatry. 2000 Dec;157(12):1994-2001.

PMID:
11097966
3.

Volumetric analysis and three-dimensional glucose metabolic mapping of the striatum and thalamus in patients with autism spectrum disorders.

Haznedar MM, Buchsbaum MS, Hazlett EA, LiCalzi EM, Cartwright C, Hollander E.

Am J Psychiatry. 2006 Jul;163(7):1252-63.

PMID:
16816232
4.

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L; STAART Psychopharmacology Network.

Arch Gen Psychiatry. 2009 Jun;66(6):583-90. doi: 10.1001/archgenpsychiatry.2009.30.

5.

A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders.

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, Wasserman S, Swanson E, Settipani C.

Am J Psychiatry. 2012 Mar;169(3):292-9. doi: 10.1176/appi.ajp.2011.10050764. Erratum in: Am J Psychiatry. 2012 May;169(5):540.

PMID:
22193531
6.

Fluoxetine versus placebo in posttraumatic stress disorder.

Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC.

J Clin Psychiatry. 2002 Mar;63(3):199-206.

PMID:
11926718
7.

Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder.

Ackerman DL, Greenland S, Bystritsky A.

J Clin Psychopharmacol. 1998 Jun;18(3):185-92.

PMID:
9617976
8.

An open trial of divalproex sodium in autism spectrum disorders.

Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S.

J Clin Psychiatry. 2001 Jul;62(7):530-4.

PMID:
11488363
9.

Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression.

Smith GS, Reynolds CF 3rd, Pollock B, Derbyshire S, Nofzinger E, Dew MA, Houck PR, Milko D, Meltzer CC, Kupfer DJ.

Am J Psychiatry. 1999 May;156(5):683-9.

PMID:
10327899
11.

Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression.

New AS, Buchsbaum MS, Hazlett EA, Goodman M, Koenigsberg HW, Lo J, Iskander L, Newmark R, Brand J, O'Flynn K, Siever LJ.

Psychopharmacology (Berl). 2004 Nov;176(3-4):451-8. Epub 2004 May 25.

PMID:
15160265
12.

Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.

Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang SJ, Altemus M, Murphy DL.

Psychopharmacology (Berl). 1998 Dec;140(4):434-44.

PMID:
9888619
13.

Fluoxetine for Autistic Behaviors (FAB trial): study protocol for a randomized controlled trial in children and adolescents with autism.

Mouti A, Reddihough D, Marraffa C, Hazell P, Wray J, Lee K, Kohn M.

Trials. 2014 Jun 16;15:230. doi: 10.1186/1745-6215-15-230.

14.

Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J; Treatment for Adolescents With Depression Study (TADS) Team.

JAMA. 2004 Aug 18;292(7):807-20.

PMID:
15315995
15.

Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex.

Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M, Najafi A, Klein E, Hazen K, Bunney WE Jr, Fallon JH, Keator D.

Am J Psychiatry. 1999 Aug;156(8):1149-58. Erratum in: Am J Psychiatry 1999 Oct;156(10):1666.

PMID:
10450253
16.

Characteristics of fluoxetine versus placebo responders in a randomized trial of geriatric depression.

Ackerman DL, Greenland S, Bystritsky A, Small GW.

Psychopharmacol Bull. 1997;33(4):707-14.

PMID:
9493483
17.

Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study.

Murphy DG, Daly E, Schmitz N, Toal F, Murphy K, Curran S, Erlandsson K, Eersels J, Kerwin R, Ell P, Travis M.

Am J Psychiatry. 2006 May;163(5):934-6.

PMID:
16648340
18.

A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.

Phillips KA, Albertini RS, Rasmussen SA.

Arch Gen Psychiatry. 2002 Apr;59(4):381-8.

PMID:
11926939
19.

A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.

Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R.

Neuropsychopharmacology. 2005 Mar;30(3):582-9.

20.

Supplemental Content

Support Center